Breast Cancer Clinical Trial

Clinical Trial Finder Breast Cancer Trials

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

See Locations Near You

Summary

The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Patients with metastatic or advanced solid tumors
Women with histologically or cytologically confirmed triple negative breast carcinoma
Participants with histologically or cytologically confirmed pancreatic adenocarcinoma
Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)

Exclusion Criteria:

Active brain metastases or leptomeningeal metastases.
Any serious or uncontrolled medical disorder
Prior malignancy active within the previous 3 years

Other protocol defined inclusion/exclusion criteria could apply

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

105

Study ID:

NCT03098550

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 20 Locations for this study

See Locations Near You

Pacific Shores Medical Group
Long Beach California, 90813, United States
University Of Colorado
Aurora Colorado, 80045, United States
Moffitt Cancer Center
Tampa Florida, 33612, United States
University Of Michigan
Ann Arbor Michigan, 48109, United States
Providence Portland Medical Center
Portland Oregon, 97213, United States
Local Institution
St Leonards New South Wales, 2065, Australia
Local Institution
Edmonton , T6G 1, Canada
Local Institution
Lyon Cedex 08 , 69373, France
Local Institution
Marseille Cedex 9 , 13273, France
Centre Paul Strauss
Strasbourg Cedex , 67085, France
Universitaetsklinikum Carl Gustav Carus
Dresden , 01307, Germany
Medizinische Universitaetsklinik Freiburg
Freiburg , 79106, Germany
Universitaetsklinik Heidelberg
Heidelberg , 69120, Germany
Local Institution
Milano , 20132, Italy
Istituto Nazionale Tumori Fondazione Pascale
Napoli , 80131, Italy
Fundacion De Investigacion
San Juan , 00927, Puerto Rico
Hospital Gral. Univ. Gregorio Maranon
Madrid , 28007, Spain
Local Institution
Majadahonda - Madrid , 28222, Spain
Klinik Fur Onkologie
Basel , 4031, Switzerland
University Hospital of Lausanne
Lausanne , 1011, Switzerland
Load More

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

105

Study ID:

NCT03098550

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials for Breast Cancer
Have You Been Diagnosed With Late-Stage Breast Cancer? Know That You Have Treatment Options.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider